ICER Evaluated New Hypertension Treatments
The Institute for Clinical and Economic Review issued an evidence report comparing the value of two hypertension drugs.
Updated on Oct. 2, 2026 in Healthcare
Live Poll
Should pharmaceutical companies be held to independent fair price benchmarks for new medications?
The Institute for Clinical and Economic Review (ICER) released a new evidence report assessing the benefits and risks of the hypertension medications baxdrostat and lorundrostat. The report provides a benchmark for pricing based on health improvement.
Why it matters
This report establishes a recommended fair price range for the drug baxdrostat, which currently carries a high annual list price. It serves as a guide for stakeholders to evaluate whether treatment costs align with demonstrated health benefits.
AstraZeneca set the annual list price for the FDA-approved drug baxdrostat at $10,950. The report concludes that a 78-87% discount is necessary for the treatment to meet ICER's defined fair price range.
The players
Institute for Clinical and Economic Review
This Boston-based organization evaluates the clinical and economic value of medical interventions to provide evidence-based recommendations.
AstraZeneca
This multinational pharmaceutical and biotechnology company is the manufacturer of the hypertension treatment baxdrostat.
Midwest CEPAC
This is a regional appraisal committee that reviews evidence reports to discuss how new therapies fit into the broader healthcare landscape.
The details
ICER analyzed clinical data to measure the value of these interventions after incorporating feedback from a four-week public comment period. While baxdrostat is already FDA-approved, lorundrostat remains in development and lacks formal approval.
Timeline
October 1, 2026: The Institute for Clinical and Economic Review posted the revised evidence report.
October 29, 2026: The Midwest CEPAC will hold a public meeting to review the findings.
Market Landscape
This assessment aligns with the growing national focus on drug-price transparency and the government’s move to curb costs for expensive therapies. It follows a pattern established by the Inflation Reduction Act's Medicare drug-price negotiation provisions by demanding greater value from manufacturers.
This report acts as a benchmark that could influence future negotiations between insurers and manufacturers regarding the cost of hypertension care. Patients and providers may see this data used to argue for lower out-of-pocket costs or more affordable treatment tiers.
The takeaway
The report highlights the significant gap between current market pricing for new hypertension medications and their calculated clinical value. Consumers and providers can use these findings to better understand the justification behind pharmaceutical costs and the importance of evidence-based pricing.
What happens next
The Midwest CEPAC is scheduled to hold a public meeting to deliberate on the findings of this report on October 29, 2026.
Further reading
For more on industry analysis, explore the Healthcare section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should pharmaceutical companies be held to independent fair price benchmarks for new medications?
